Scientists isolate tiny antibody that neutralizes SARS-CoV-
Sept 15, 2020 20:43:58 GMT
sgard434 and icemandios like this
Post by miamianne67 on Sept 15, 2020 20:43:58 GMT
From Seeking Alfa
Scientists isolate tiny antibody that neutralizes SARS-CoV-2
Sep. 15, 2020 4:19 PM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor
Scientists at the University of Pittsburgh School of Medicine (UPMC) have isolated an antibody, dubbed Ab8, that is 10x smaller than a full-sized antibody used in drugs and completely neutralizes the SARS-CoV-2 virus.
The data, published in the journal Cell, showed that Ab8 was highly effective in preventing and treating COVID-19 in mice and hamsters.
The scientists says Ab8's small size increases its potential for diffusion in tissues, increasing efficacy, while being potentially suitable for alternative routes of administration such as inhalation. A bonus is that it does not bind to human cells, thereby avoiding unwanted side effects.
Ab8 was identified by "fishing" in a pool of more than 100B potential candidates using the SARS-CoV-2 spike protein as bait. It is created when the VH domain is fused to part of the immunoglobulin tail region, adding the immune functions of a full-sized antibody without the bulk.
Abound Bio, a newly formed UPMC-backed company, has in-licensed the rights to Ab8 for global development.
Selected tickers: Eli Lilly (NYSE:LLY), Gilead Sciences (NASDAQ:GILD), Vir Biotechnology (NASDAQ:VIR), Regeneron Pharmaceuticals (NASDAQ:REGN)
Scientists isolate tiny antibody that neutralizes SARS-CoV-2
Sep. 15, 2020 4:19 PM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor
Scientists at the University of Pittsburgh School of Medicine (UPMC) have isolated an antibody, dubbed Ab8, that is 10x smaller than a full-sized antibody used in drugs and completely neutralizes the SARS-CoV-2 virus.
The data, published in the journal Cell, showed that Ab8 was highly effective in preventing and treating COVID-19 in mice and hamsters.
The scientists says Ab8's small size increases its potential for diffusion in tissues, increasing efficacy, while being potentially suitable for alternative routes of administration such as inhalation. A bonus is that it does not bind to human cells, thereby avoiding unwanted side effects.
Ab8 was identified by "fishing" in a pool of more than 100B potential candidates using the SARS-CoV-2 spike protein as bait. It is created when the VH domain is fused to part of the immunoglobulin tail region, adding the immune functions of a full-sized antibody without the bulk.
Abound Bio, a newly formed UPMC-backed company, has in-licensed the rights to Ab8 for global development.
Selected tickers: Eli Lilly (NYSE:LLY), Gilead Sciences (NASDAQ:GILD), Vir Biotechnology (NASDAQ:VIR), Regeneron Pharmaceuticals (NASDAQ:REGN)
